Investors' Biggest Worry About GW Pharmaceuticals Could Be the Biotech's Ace in the Hole

GW Pharmaceuticals' (NASDAQ: GWPH) stock soared more than 60% last year. So far in 2017, though, shares of the cannabinoid-focused biotech are down rather than up. One possible reason behind GW Pharma's lackluster year-to-date performance is that some investors are worried about the impact of drug-drug interactions with the company's lead candidate Epidiolex.

Executives from GW Pharma had the opportunity to discuss Epidiolex and investors' concerns at the Morgan Stanley healthcare conference on Wednesday. Interestingly, based on their comments, the big worry for investors just might turn out to be an ace in the hole for GW in fending off rivals for Epidiolex. Here's how.

Image source: Getty Images.

Source: Fool.com